NIH invests $19.2M in HIV vaccine R&D, facing long development cycles and high scientific risk

Contract Overview

Contract Amount: $19,188,157 ($19.2M)

Contractor: Profectus Biosciences, Inc.

Awarding Agency: Department of Health and Human Services

Start Date: 2008-09-01

End Date: 2013-12-31

Contract Duration: 1,947 days

Daily Burn Rate: $9.9K/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 19

Pricing Type: COST NO FEE

Sector: R&D

Official Description: THERAPEUTIC IMMUNIZATION AGAINST HIV WITH ADJUVANT-ENHANCED DNA AND MULTI-EPITOPE PEPTIDE VACCINES

Place of Performance

Location: BALTIMORE, BALTIMORE CITY County, MARYLAND, 21224

State: Maryland Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $19.2 million to PROFECTUS BIOSCIENCES, INC. for work described as: THERAPEUTIC IMMUNIZATION AGAINST HIV WITH ADJUVANT-ENHANCED DNA AND MULTI-EPITOPE PEPTIDE VACCINES Key points: 1. Contract awarded for research and development of therapeutic immunization against HIV. 2. Significant investment reflects the high-risk, high-reward nature of vaccine development. 3. Long contract duration (1947 days) suggests a complex, multi-stage research process. 4. Focus on advanced vaccine technologies like adjuvant-enhanced DNA and multi-epitope peptides. 5. Potential for breakthrough in HIV prevention, though success is not guaranteed. 6. Contract type indicates a commitment to a specific research path over a defined period.

Value Assessment

Rating: fair

The contract value of $19.2 million over approximately 5.3 years represents a substantial investment in a single R&D project. Benchmarking this against other early-stage vaccine development contracts is challenging due to the unique nature of HIV research and the specific technological approaches. The 'Cost No Fee' (Cost-Plus-Fixed-Fee) contract type suggests that the government is primarily covering the costs incurred by the contractor, with a fixed fee for profit, which is common in R&D where outcomes are uncertain. Without more comparable contracts for similar HIV vaccine research, a precise value-for-money assessment is difficult, but the investment level aligns with the complexity and potential impact of developing an HIV vaccine.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple vendors had the opportunity to bid. This process is designed to foster a competitive environment, potentially leading to better pricing and innovative solutions. The fact that it was competed suggests that the government sought the best available research capabilities for this critical area. The number of bidders is not specified, but the full and open nature is a positive indicator for the procurement process.

Taxpayer Impact: Full and open competition generally benefits taxpayers by encouraging a wider range of proposals and potentially driving down costs through market forces, although in R&D, the focus is often on technical merit and innovation rather than just the lowest price.

Public Impact

The primary beneficiaries are individuals at risk of HIV infection and the broader public health community, through the potential development of a preventative vaccine. The service delivered is advanced scientific research and development aimed at creating a novel therapeutic immunization. The geographic impact is global, as an effective HIV vaccine would address a worldwide health crisis. Workforce implications include employment for scientists, researchers, and support staff within the contracting organization and potentially related research institutions.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

High scientific uncertainty inherent in vaccine development, particularly for complex viruses like HIV.
Long development timelines increase the risk of obsolescence or the emergence of more effective alternative treatments.
Potential for cost overruns in complex R&D projects, even with cost-plus contract types.

Positive Signals

Investment in cutting-edge vaccine technology holds potential for significant public health breakthroughs.
Full and open competition suggests a robust selection process for the most capable research team.
NIH's commitment to R&D in critical health areas demonstrates a proactive approach to major diseases.

Sector Analysis

This contract falls within the Biotechnology and Life Sciences sector, specifically focusing on pharmaceutical R&D. The market for vaccine development is highly specialized, characterized by long development cycles, significant regulatory hurdles, and substantial R&D investment. Comparable spending benchmarks are difficult to establish precisely due to the unique nature of HIV vaccine research, but investments in novel therapeutic areas often run into tens or hundreds of millions of dollars over several years. This contract represents a focused effort within a broader government strategy to combat HIV/AIDS through scientific advancement.

Small Business Impact

There is no indication that this contract involved small business set-asides. The nature of advanced biotechnology R&D often requires specialized facilities and extensive expertise typically found in larger research organizations or established pharmaceutical companies. Subcontracting opportunities for small businesses might exist in areas like specialized testing, equipment supply, or data analysis, but the primary awardee is likely a larger entity. The impact on the small business ecosystem is likely indirect, through potential supply chain opportunities rather than direct set-aside awards.

Oversight & Accountability

Oversight for this contract would primarily be managed by the National Institutes of Health (NIH), a component of the Department of Health and Human Services. Mechanisms likely include regular progress reports, scientific reviews, and financial audits to ensure adherence to research protocols and budget. Accountability rests with the contractor to meet research milestones and with NIH to monitor progress and provide necessary guidance. Transparency is typically maintained through public research databases and scientific publications, although specific contract details might be subject to proprietary considerations.

Related Government Programs

National Institutes of Health (NIH) Research and Development Contracts
Department of Health and Human Services (HHS) Biomedical Research
HIV/AIDS Prevention and Treatment Programs
Vaccine Development Research
Biotechnology Research and Development

Risk Flags

High scientific risk associated with HIV vaccine development.
Long development timelines inherent in vaccine R&D.
Potential for technological obsolescence in a rapidly evolving scientific field.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $19.2 million to PROFECTUS BIOSCIENCES, INC.. THERAPEUTIC IMMUNIZATION AGAINST HIV WITH ADJUVANT-ENHANCED DNA AND MULTI-EPITOPE PEPTIDE VACCINES

Who is the contractor on this award?

The obligated recipient is PROFECTUS BIOSCIENCES, INC..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (National Institutes of Health).

What is the total obligated amount?

The obligated amount is $19.2 million.

What is the period of performance?

Start: 2008-09-01. End: 2013-12-31.

What is the specific scientific approach being funded by this contract for HIV vaccine development?

This contract funds research into therapeutic immunization against HIV using advanced vaccine technologies. Specifically, it focuses on adjuvant-enhanced DNA vaccines and multi-epitope peptide vaccines. Adjuvants are substances that enhance the immune response to an antigen, potentially making the vaccine more effective. DNA vaccines deliver genetic material encoding viral proteins to stimulate an immune response. Multi-epitope peptide vaccines use specific fragments (epitopes) of viral proteins designed to elicit a targeted immune reaction. This approach aims to overcome the challenges posed by HIV's genetic diversity and its ability to evade the immune system, representing a sophisticated strategy in vaccine design.

How does the contract's duration and value compare to typical R&D investments in vaccine development?

The contract duration of approximately 1947 days (over 5 years) and a value of $19.2 million are substantial for a single R&D project, but not unusual for vaccine development, especially for complex targets like HIV. Early-stage vaccine research is inherently lengthy, often spanning a decade or more from initial discovery to market approval, involving preclinical studies, multiple phases of human clinical trials, and regulatory review. The investment level reflects the high scientific risk, the need for specialized expertise, and the potential for significant public health impact. While specific benchmarks vary widely based on the disease, technology, and stage of development, this funding level is consistent with significant, multi-year R&D efforts in the pharmaceutical and biotechnology sectors.

What are the primary risks associated with this specific HIV vaccine R&D contract?

The primary risks are scientific and programmatic. Scientifically, HIV is an exceptionally challenging virus to target with a vaccine due to its high mutation rate, genetic diversity, and ability to integrate into the host genome, evading immune responses. There is no guarantee that the specific DNA and peptide-based approaches funded here will elicit a sufficiently protective or therapeutic immune response. Programmatically, R&D projects face risks of delays, cost overruns, and failure to meet interim milestones, even with careful planning. The long development timeline also means that scientific understanding or alternative therapeutic strategies could evolve, potentially diminishing the relative value of this specific approach over time.

What is the expected outcome or deliverable for this contract, and how is success measured?

The expected outcome for this contract is the advancement of therapeutic immunization against HIV through the development and testing of novel DNA and peptide-based vaccine candidates. Success is likely measured through a series of preclinical and potentially early-stage clinical milestones. These could include demonstrating the immunogenicity (ability to provoke an immune response) and safety of the vaccine candidates in laboratory models and animal studies, identifying optimal formulations and dosing regimens, and potentially gathering preliminary data on efficacy. The contract likely specifies key research objectives and performance metrics that the contractor must achieve to demonstrate progress and justify continued funding.

Has the contractor, Profectus Biosciences, Inc., had other significant federal contracts related to vaccine development?

Information regarding Profectus Biosciences, Inc.'s specific federal contract history beyond this award is not detailed in the provided data. However, companies involved in advanced biotechnology and vaccine R&D often engage in multiple government contracts, particularly with agencies like NIH, BARDA (Biomedical Advanced Research and Development Authority), and DoD (Department of Defense). A comprehensive review would require searching federal procurement databases (like SAM.gov or FPDS) for their contract portfolio. Success in one R&D contract, especially in a high-priority area like HIV, can often lead to further funding opportunities based on demonstrated capabilities and progress.

Industry Classification

NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: NIHNIAIDDAIDS0442

Offers Received: 19

Pricing Type: COST NO FEE (S)

Evaluated Preference: NONE

Contractor Details

Address: 1450 S ROLLING RD STE 1-10, BALTIMORE, MD, 21227

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Small Business

Financial Breakdown

Contract Ceiling: $19,188,157

Exercised Options: $19,188,157

Current Obligation: $19,188,157

Contract Characteristics

Commercial Item: COMMERCIAL ITEM PROCEDURES NOT USED

Cost or Pricing Data: NO

Timeline